While a number of international companies in the past five years have reinvested an increasingly larger part of their revenue in R&D, the opposite trend is evident at two of Denmarks largest pharmaceutical companies. But new strategies may change this fact in the coming years.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.